Inter-Institutional Comparison of Personalized Risk Assessments for Second Malignant Neoplasms for a 13-Year-Old Girl Receiving Proton Versus Photon Craniospinal Irradiation

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2015 Mar 13

PMID 25763928

Citations 10

Authors

Phillip J Taddei

Nabil Khater

Rui Zhang

Fady B Geara

Anita Mahajan

Wassim Jalbout

Angelica Perez-Andujar

Bassem Youssef

Wayne D Newhauser

Affiliations

Soon will be listed here.

Abstract

Children receiving radiotherapy face the probability of a subsequent malignant neoplasm (SMN). In some cases, the predicted SMN risk can be reduced by proton therapy. The purpose of this study was to apply the most comprehensive dose assessment methods to estimate the reduction in SMN risk after proton therapy vs. photon therapy for a 13-year-old girl requiring craniospinal irradiation (CSI). We reconstructed the equivalent dose throughout the patient's body from therapeutic and stray radiation and applied SMN incidence and mortality risk models for each modality. Excluding skin cancer, the risk of incidence after proton CSI was a third of that of photon CSI. The predicted absolute SMN risks were high. For photon CSI, the SMN incidence rates greater than 10% were for thyroid, non-melanoma skin, lung, colon, stomach, and other solid cancers, and for proton CSI they were non-melanoma skin, lung, and other solid cancers. In each setting, lung cancer accounted for half the risk of mortality. In conclusion, the predicted SMN risk for a 13-year-old girl undergoing proton CSI was reduced vs. photon CSI. This study demonstrates the feasibility of inter-institutional whole-body dose and risk assessments and also serves as a model for including risk estimation in personalized cancer care.

Citing Articles

Impaired DNA Double-Strand Break Repair in Irradiated Sheep Lung Fibroblasts: Late Effects of Previous Irradiation of the Spinal Thecal Sac.

Youssef B, Feghaly C, Al Choboq J, Bou-Gharios J, Challita R, Azzi J Cancers (Basel). 2024; 16(17).

PMID: 39272826 PMC: 11394103. DOI: 10.3390/cancers16172968.

Assessment of peripheral dose as a function of distance and depth from cobalt-60 beam in water phantom using TLD-100.

Ahmad H, Ali J, Ahmad K, Biradar G, Zaman A, Uddin Y J Egypt Natl Canc Inst. 2024; 36(1):22.

PMID: 38910202 DOI: 10.1186/s43046-024-00227-1.

A simple analytical model for a fast 3D assessment of peripheral photon dose during coplanar isocentric photon radiotherapy.

Sanchez-Nieto B, Lopez-Martinez I, Rodriguez-Mongua J, Espinoza I Front Oncol. 2022; 12:872752.

PMID: 36276161 PMC: 9583866. DOI: 10.3389/fonc.2022.872752.

Adult Medulloblastoma: Updates on Current Management and Future Perspectives.

Franceschi E, Giannini C, Furtner J, Pajtler K, Asioli S, Guzman R Cancers (Basel). 2022; 14(15).

PMID: 35954372 PMC: 9367316. DOI: 10.3390/cancers14153708.

Radiotherapy in Medulloblastoma-Evolution of Treatment, Current Concepts and Future Perspectives.

Seidel C, Heider S, Hau P, Glasow A, Dietzsch S, Kortmann R Cancers (Basel). 2021; 13(23).

PMID: 34885055 PMC: 8657317. DOI: 10.3390/cancers13235945.

References

Perkins J, Liu Y, Mitby P, Neglia J, Hammond S, Stovall M . Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2005; 23(16):3733-41. DOI: 10.1200/JCO.2005.06.237. View

Howell R, Giebeler A, Koontz-Raisig W, Mahajan A, Etzel C, DAmelio Jr A . Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiat Oncol. 2012; 7:116. PMC: 3430590. DOI: 10.1186/1748-717X-7-116. View

Taddei P, Howell R, Krishnan S, Scarboro S, Mirkovic D, Newhauser W . Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol. 2010; 55(23):7055-65. PMC: 3001302. DOI: 10.1088/0031-9155/55/23/S07. View

Miralbell R, Lomax A, Cella L, Schneider U . Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys. 2002; 54(3):824-9. DOI: 10.1016/s0360-3016(02)02982-6. View

Spruijt K, Dahele M, Cuijpers J, Jeulink M, Rietveld D, Slotman B . Flattening filter free vs flattened beams for breast irradiation. Int J Radiat Oncol Biol Phys. 2012; 85(2):506-13. DOI: 10.1016/j.ijrobp.2012.03.040. View

Mahajan A . Normal tissue complications from low-dose proton therapy. Health Phys. 2012; 103(5):586-9. DOI: 10.1097/HP.0b013e3182611114. View

Stankovskiy A, Kerhoas-Cavata S, Ferrand R, Nauraye C, Demarzi L . Monte Carlo modelling of the treatment line of the Proton Therapy Center in Orsay. Phys Med Biol. 2009; 54(8):2377-94. DOI: 10.1088/0031-9155/54/8/008. View

Zhang R, Fontenot J, Mirkovic D, Hendricks J, Newhauser W . ADVANTAGES OF MCNPX-BASED LATTICE TALLY OVER MESH TALLY IN HIGH-SPEED MONTE CARLO DOSE RECONSTRUCTION FOR PROTON RADIOTHERAPY. Nucl Technol. 2014; 183(1):101-106. PMC: 4244884. DOI: 10.13182/nt13-a16995. View

Taddei P, Mahajan A, Mirkovic D, Zhang R, Giebeler A, Kornguth D . Predicted risks of second malignant neoplasm incidence and mortality due to secondary neutrons in a girl and boy receiving proton craniospinal irradiation. Phys Med Biol. 2010; 55(23):7067-80. PMC: 3001324. DOI: 10.1088/0031-9155/55/23/S08. View

10.

Brenner D, Elliston C, Hall E, BERDON W . Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001; 176(2):289-96. DOI: 10.2214/ajr.176.2.1760289. View

11.

Stokkevag C, Engeseth G, Ytre-Hauge K, Rohrich D, Odland O, Muren L . Estimated risk of radiation-induced cancer following paediatric cranio-spinal irradiation with electron, photon and proton therapy. Acta Oncol. 2014; 53(8):1048-57. DOI: 10.3109/0284186X.2014.928420. View

12.

Armstrong G, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S . Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2011; 29(22):3056-64. PMC: 3157966. DOI: 10.1200/JCO.2011.34.6585. View

13.

Law M, Liu B . Informatics in radiology: DICOM-RT and its utilization in radiation therapy. Radiographics. 2009; 29(3):655-67. DOI: 10.1148/rg.293075172. View

14.

Merchant T, Farr J . Proton beam therapy: a fad or a new standard of care. Curr Opin Pediatr. 2013; 26(1):3-8. DOI: 10.1097/MOP.0000000000000048. View

15.

Meadows A, Friedman D, Neglia J, Mertens A, Donaldson S, Stovall M . Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27(14):2356-62. PMC: 2738645. DOI: 10.1200/JCO.2008.21.1920. View

16.

Taddei P, Mirkovic D, Fontenot J, Giebeler A, Zheng Y, Kornguth D . Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams. Phys Med Biol. 2009; 54(8):2259-75. PMC: 4142507. DOI: 10.1088/0031-9155/54/8/001. View

17.

Newhauser W, Rechner L, Mirkovic D, Yepes P, Koch N, Titt U . Benchmark measurements and simulations of dose perturbations due to metallic spheres in proton beams. Radiat Meas. 2014; 58:37-44. PMC: 4136527. DOI: 10.1016/j.radmeas.2013.08.001. View

18.

. Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (w(R)). A report of the International Commission on Radiological Protection. Ann ICRP. 2003; 33(4):1-117. DOI: 10.1016/s0146-6453(03)00024-1. View

19.

Fontenot J, Bloch C, Followill D, Titt U, Newhauser W . Estimate of the uncertainties in the relative risk of secondary malignant neoplasms following proton therapy and intensity-modulated photon therapy. Phys Med Biol. 2010; 55(23):6987-98. PMC: 4134093. DOI: 10.1088/0031-9155/55/23/S02. View

20.

Zheng Y, Newhauser W, Fontenot J, Taddei P, Mohan R . Monte Carlo study of neutron dose equivalent during passive scattering proton therapy. Phys Med Biol. 2007; 52(15):4481-96. DOI: 10.1088/0031-9155/52/15/008. View